The fact that healthcare organizations need to improve care outcomes is undeniably undisputed. To succeed, health plan leaders need to acknowledge that medical care is estimated to account for only 10% to 20% of the modifiable contributors to healthy outcomes for a population. The other 80% to 90% emanates from social determinants of health (SDOH),…

Introduction In today’s highly competitive healthcare marketing industry, marketers need to take a strategic approach to audience development that accounts for the intersection of factors that impact the provider’s ability to treat the patient, the marketer’s capacity to engage the attention of the healthcare provider, and the “knowability” of these factors. Drawing from the work…

The COVID-19 pandemic underscored the necessity for healthcare organizations to adapt swiftly. This was particularly evident with the rapid adoption of telehealth. For instance, in the first quarter of 2020, telehealth visits surged by 50% compared to 2019. As COVID-19 becomes endemic, healthcare leaders face crucial decisions on the strategic use of telehealth versus in-person…

Cookie-less Marketing for Pharmaceuticals and the Role of Real-World Data (RWD) Life Sciences Pharmaceutical marketing is undergoing a significant transformation as third-party cookies become obsolete. To navigate this shift, pharmaceutical companies must embrace cookie-less marketing strategies, leveraging real-world data throughout the advertising campaign lifecycle.  In this whitepaper, we explore: The impact of cookie-less marketing on…

Impact of Applying SDOH on Prescription Fill Rate Analysis Life Sciences This whitepaper highlights the significance of understanding prescription rejection rates, particularly for specialty pharmacy medications, and the role of plan design and social determinants of health (SDOH) in determining eligibility and out-of-pocket costs for patients.   Traditional analyses focusing solely on demographics like age and…

New Treatments Hold Significant Promise, but are Marketing Teams Helping Life Sciences Companies Deliver on this Potential? Life Sciences Download

Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year.

Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. This illness often begins with little or no symptoms, meaning patients and their doctors discover it when it’s too late for preventative treatment. Conducting successful ovarian cancer clinical trials can help us uncover new treatments and save lives — but…